“Cell Therapy Primed Liver Transplant Patients to Avoid Organ Rejection, Small Study Shows ” — what this page in the network covers. A pioneering small study published in Nature Medicine demonstrates that a novel cell therapy, using expanded regulatory T cells (Tregs) administered befo... A pioneering small study published in Nature Medicine demonstrates that a novel cell therapy, using expanded regulatory T cells (Tregs) administered before liver transplantation, may enable patients to reduce or eliminate their need for lifelong immunosuppressive drugs.
Researchers at the University of Pittsburgh observed that a significant portion of the 16 participants successfully ceased immunosuppressants within six months post-transplant, experiencing comparable outcomes without the typical side effects. This breakthrough offers a potential paradigm shift in transplantation, aiming to induce immune tolerance rather than broadly suppress the immune system, thereby mitigating risks of infection, cancer, and the financial burden associated with long-term immunosuppression. The full version stays on the original page, which this listing opens directly.